Adult

Ocular Toxoplasmosis

 Guideline for Ophthalmology use only. 

  • Always speak to Micro/ID on suspicion of ocular toxoplasmosis.
  • In cases of newly acquired toxoplasmosis during pregnancy – inform uveitis consultant and obstetrician consultant. The following regimens are not recommended in pregnancy. Consult Micro/ID for alternatives.  
  • In immunocompromised patients (always suspect in large, multiple and bilateral lesions with or without scars) inform the treating physician and arrange brain imaging to rule out CNS involvement (56% risk of cerebral involvement in patients with HIV). Treat as per protocol for sight threatening lesions. Inform uveitis consultant. 
  • Do not use systemic corticosteroids without antimicrobial coverage because of the potential for severe panophthalmitis.
  • Do not use long acting periocular and/or intraocular steroids (such as triamcinolone acetonide) because of the potential for severe panophthalmitis.

Preferred

pyrimethamine* 100mg po STAT, then 25mg po od

PLUS

Sulfadiazine 3g po STAT, then 1g po tds 

PLUS

Folinic acid 15mg po od  

PLUS

Prednisolone 0.5mg/kg-1mg/kg po od (max dose 60mg per day, slow taper) to commence after 48 hours of antibiotic therapy.

 

*Pyrimethamine can cause myelosuppression: repeat FBC every 2 weeks during treatment.  

Alternatives

First line

co-trimoxazole 960mg po bd

PLUS Prednisolone 0.5mg/kg-1mg/kg po od (max dose 60mg per day, slow taper) to commence after 48 hours of antibiotic therapy.

 

Second line

azithromycin 500mg po STAT, then azithromycin 250mg po od for 5 weeks. 

PLUS Prednisolone 0.5mg/kg-1mg/kg po od (max dose 60mg per day, slow taper) to commence after 48 hours of antibiotic therapy.

 

If patient is not responding to alternative treatment options, speak to Micro/ID and Ophthalmology. 

Toxoplasmosis prophylaxis

Need for prophylaxis to be decided by consultant ophthalmologist and Micro/ID

Primary prophylaxis

co-trimoxazole 960mg po od three times per week or 480mg po od

 

If co-trimoxazole is not suitable, contact Micro/ID for alternative options.

Editorial Information

Last reviewed: 01 Jul 2024